How Trump’s EU tariffs could affect drug prices: What it means for Ozempic, Botox, brandname prescriptions

A new trade deal imposing a 15% tariff on EU imports, including pharmaceuticals, is expected to drive up prices for brand-name drugs in the U.S. Experts indicate that nearly half of the active ingredients and final manufacturing for high-cost medications like Ozempic and Wegovy originate in Europe, prompting drug companies to likely increase list prices. This tariff primarily impacts brand-name drugs, which account for 80% of U.S. drug spending, while generic drug prices are largely unaffected given their diverse global supply chain.

Analysis

A new trade deal imposing a 15% tariff on European Union imports presents a significant headwind for U.S.-marketed, EU-manufactured pharmaceuticals. The EU is a critical manufacturing hub, producing nearly half of the active ingredients for brand-name drugs consumed in the United States. This tariff directly impacts companies like Novo-Nordisk, whose blockbuster drugs Ozempic and Wegovy are produced in Denmark, and Merck, which manufactures its cancer drug Keytruda in Ireland, although some of that production has shifted domestically. The financial implications are notable, as brand-name drugs account for approximately 80% of total U.S. drug spending despite representing only 10% of prescriptions. Experts anticipate that pharmaceutical companies will pass this cost increase on to consumers by raising list prices. In contrast, the generic drug market is expected to be largely insulated from this specific tariff, as the majority of generics are manufactured in non-EU countries such as China and India. The 15% rate, while impactful, is substantially lower than the 200% tariff previously threatened, mitigating what could have been a more severe disruption.

Key Decisions for Investors

• Investors should immediately assess the EU manufacturing footprint of their pharmaceutical holdings, as companies like Novo-Nordisk with significant production in the region face direct margin pressure or will need to enact price hikes.
• Monitor company communications from exposed firms like Merck and Novo-Nordisk for guidance on pricing strategy and the expected pass-through of tariff costs to gauge the ultimate impact on profitability.
• Consider the relative insulation of generic drug manufacturers from this specific tariff, which may present a defensive positioning opportunity against brand-name pharma exposed to EU-US trade friction.
• Recognize that while this 15% tariff is a negative catalyst, the de-escalation from a previously threatened 200% tariff may limit further downside for affected stocks.